Figure 1.

BCR-ABL1 DTs in patients failing IM and 2G TKIs in second line. (A) Three hundred five patients with chronic phase CML presenting BCR-ABL1/ABL1^IS values ≤ 0.1% on IM therapy were included in this analysis. One hundred eighteen patients failed IM and switched to a different therapy, while 187 individuals displayed an increase in BCR-ABL1 levels but retained their previously acquired MR^3.0. Of the 118 individuals failing IM, 21 also failed the 2G TKI prescribed in second line while 76 responded to treatment. The remaining 21 patients either received ponatinib (n = 10) or were subjected to allogeneic human stem cell transplant (HSCT: n = 11). Boxplots delimited by the 25th (lower) and 75th (upper) percentile comparing BCR-ABL1 DTs in the IM failure group and in subjects maintaining their MR^3.0 (B) or in the IM failure group and in individuals failing 2G TKIs in second line (C). Horizontal lines above and below each boxplot indicate the 5th and 95th percentile, respectively. Numbers inside each boxplot represent median values observed within each patient cohort. The reported p-values indicate statistical significance between the two patient groups included in each panel.